ClearPoint Neuro director granted 12,820 RSUs

FALLON LYNNETTE C reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

FALLON LYNNETTE C reported acquisition or exercise transactions in this Form 4 filing.

ClearPoint Neuro director Lynnette C. Fallon received a grant of 12,820 restricted stock units of common stock. Each unit represents a right to receive one CLPT share. The RSUs vest on the earlier of the first anniversary of the grant date or the day before the company’s 2027 annual meeting.

Insights

Equity compensation analyst

Director received routine RSU equity compensation with time-based vesting.

ClearPoint Neuro granted 12,820 restricted stock units to director Lynnette C. Fallon as compensation. RSUs are common for aligning directors’ interests with shareholders, and this grant was made at no cash cost to the insider.

The RSUs vest on the earlier of the first anniversary of the grant date or the day immediately preceding the company’s 2027 annual meeting of stockholders. This is a standard time-based vesting schedule, and there are no open‑market purchases or sales disclosed in this filing.

Insider Trade Summary

Grant/Award: 12,820 shares

Grant/Award 1 txn

Insider FALLON LYNNETTE C

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	12,820	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 12,820 contracts (Direct)

Footnotes (2)

1. F1. Each restricted stock unit represents a contingent right to receive one share of CLPT common stock.
2. F2. The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2027 annual meeting of stockholders.

Key Figures

RSUs granted: 12,820 units Grant price: $0.00 per unit Underlying shares: 12,820 shares +1 more

4 metrics

RSUs granted 12,820 units Restricted stock units granted to director on May 21, 2026

Grant price $0.00 per unit Equity compensation award with no cash paid by insider

Underlying shares 12,820 shares Each RSU represents one share of common stock

Holdings after grant 12,820 RSUs Total restricted stock units following this transaction

Key Terms

Restricted Stock Units, contingent right, vest, annual meeting of stockholders

4 terms

Restricted Stock Units financial

"Each restricted stock unit represents a contingent right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"represents a contingent right to receive one share of CLPT common stock"

vest financial

"The restricted stock units vest on the earlier of the first anniversary"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

annual meeting of stockholders financial

"the day immediately preceding the Company's 2027 annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ClearPoint Neuro (CLPT) director Lynnette C. Fallon report in this Form 4?

Director Lynnette C. Fallon reported receiving 12,820 restricted stock units of ClearPoint Neuro common stock. These RSUs are a stock-based compensation award and do not involve an open-market purchase or sale, but increase her equity-linked interest in the company.

How many restricted stock units did CLPT grant to director Lynnette C. Fallon?

ClearPoint Neuro granted Lynnette C. Fallon 12,820 restricted stock units tied to its common stock. Each unit represents a contingent right to receive one CLPT share, subject to the vesting conditions described in the Form 4 footnotes and the company’s equity plan.

When do Lynnette C. Fallon’s ClearPoint Neuro restricted stock units vest?

The 12,820 restricted stock units vest on the earlier of two dates. They vest either on the first anniversary of the grant date or on the day immediately preceding ClearPoint Neuro’s 2027 annual meeting of stockholders, whichever occurs first under the award terms.

Does the Form 4 for CLPT show Lynnette C. Fallon buying or selling shares on the market?

The Form 4 does not show any open-market buying or selling by Lynnette C. Fallon. It reports a grant of 12,820 restricted stock units as a compensation award, which is classified as an acquisition but not a market transaction in the company’s stock.

What does each ClearPoint Neuro restricted stock unit granted to Lynnette C. Fallon represent?

Each restricted stock unit granted to Lynnette C. Fallon represents a contingent right to receive one share of ClearPoint Neuro common stock. Actual share delivery depends on the RSUs vesting, following the time-based schedule tied to the grant date and 2027 annual meeting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/26/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FALLON LYNNETTE C

(Last) (First) (Middle)

C/O CLEARPOINT NEURO, INC.

120 S. SIERRA AVE., SUITE 100

(Street)

SOLANA BEACH CALIFORNIA 92075

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ClearPoint Neuro, Inc. [ CLPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	05/21/2026		A		12,820		(2)	(2)	Common Stock	12,820	$0	12,820	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of CLPT common stock.

2. The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2027 annual meeting of stockholders.

	/s/ Danilo D'Alessandro, by Power of Attorney for Lynnette C. Fallon	05/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)